1085 related articles for article (PubMed ID: 30694754)
21. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
22. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
23. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
Luo H; Wei W; Ye Z; Zheng J; Xu RH
Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
[TBL] [Abstract][Full Text] [Related]
24. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
25. Technical considerations for circulating tumor DNA detection in oncology.
Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
[TBL] [Abstract][Full Text] [Related]
26. Circulating biomarkers for early detection and clinical management of colorectal cancer.
Marcuello M; Vymetalkova V; Neves RPL; Duran-Sanchon S; Vedeld HM; Tham E; van Dalum G; Flügen G; Garcia-Barberan V; Fijneman RJ; Castells A; Vodicka P; Lind GE; Stoecklein NH; Heitzer E; Gironella M
Mol Aspects Med; 2019 Oct; 69():107-122. PubMed ID: 31189073
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer.
Nordgård O; Tjensvoll K; Gilje B; Søreide K
Br J Surg; 2018 Jan; 105(2):e110-e120. PubMed ID: 29341153
[TBL] [Abstract][Full Text] [Related]
29. Aberrant circulating tumor DNA methylation and exosomal microRNA biomarkers for early detection of colorectal cancer.
Zhang X; Hou H; Jiang M; Zhang X
Mol Biol Rep; 2023 Mar; 50(3):2743-2750. PubMed ID: 36583782
[TBL] [Abstract][Full Text] [Related]
30. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
31. Blood Collection and Cell-Free DNA Isolation Methods Influence the Sensitivity of Liquid Biopsy Analysis for Colorectal Cancer Detection.
Barták BK; Kalmár A; Galamb O; Wichmann B; Nagy ZB; Tulassay Z; Dank M; Igaz P; Molnár B
Pathol Oncol Res; 2019 Jul; 25(3):915-923. PubMed ID: 29374860
[TBL] [Abstract][Full Text] [Related]
32. Detection of Circulating Tumor DNA Methylation in Diagnosis of Colorectal Cancer.
Xu F; Yu S; Han J; Zong M; Tan Q; Zeng X; Fan L
Clin Transl Gastroenterol; 2021 Aug; 12(8):e00386. PubMed ID: 34382948
[TBL] [Abstract][Full Text] [Related]
33. Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy.
Verbanac D; Čeri A; Hlapčić I; Shakibaei M; Brockmueller A; Krušlin B; Ljubičić N; Baršić N; Detel D; Batičić L; Rumora L; Somborac-Bačura A; Štefanović M; Ćelap I; Demirović A; Petlevski R; Petrik J; Grdić Rajković M; Hulina-Tomašković A; Rako I; Saso L; Barišić K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919272
[TBL] [Abstract][Full Text] [Related]
34. Cell-Free DNA in the Management of Colorectal Cancer.
Harlé A
Recent Results Cancer Res; 2020; 215():253-261. PubMed ID: 31605233
[TBL] [Abstract][Full Text] [Related]
35. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
36. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
[TBL] [Abstract][Full Text] [Related]
37. Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel.
Constâncio V; Nunes SP; Moreira-Barbosa C; Freitas R; Oliveira J; Pousa I; Oliveira J; Soares M; Dias CG; Dias T; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2019 Dec; 11(1):175. PubMed ID: 31791387
[TBL] [Abstract][Full Text] [Related]
38. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
[TBL] [Abstract][Full Text] [Related]
40. Liquid biopsy in colorectal cancer: Onward and upward.
Torresan S; de Scordilli M; Bortolot M; Di Nardo P; Foltran L; Fumagalli A; Guardascione M; Ongaro E; Puglisi F
Crit Rev Oncol Hematol; 2024 Feb; 194():104242. PubMed ID: 38128627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
